Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:6/12/2008

's ataxia. Over the past year, we made significant progress in identifying advanced leads through multiple rounds of novel compound library synthesis and screening for potency, specificity, metabolism and pharmacology. Over the next year these advanced leads will be further characterized in animal models for their pharmacologic, toxicologic and pharmacodynamic profiles to identify an appropriate candidate for the clinic. We have also received a grant from Go FAR to develop a biomarker tool which may be useful in monitoring the biochemical activity and guiding the dosing frequency of a clinical candidate in patients. Go FAR (Friedreich's Ataxia Research) is a fundraising organization headquartered in Turin, Italy formed by the non-profit group RUDI Onlus Committee, dedicated to raising donations to fund research and development of treatments for Friedreich's ataxia.

Intellectual Property

CTLA4-Ig Patent

In April, we reached a settlement with Bristol-Myers Squibb Company (Bristol) in our lawsuit alleging infringement of U.S. Patent No. 6,685,941, based on Bristol's sale of Orencia(R) for the treatment of rheumatoid arthritis. The settlement provided for Bristol to make an initial payment of $5,000,000 and to pay royalties on the U.S. net sales of Orencia(R) for any clinical indication at a rate of 1.8% for the first $500,000,000 of annual net sales, 2.0% for the next $500,000,000 of annual net sales and 4% of annual net sales in excess of $1 billion for each year until December 31, 2013. Based on analysts' estimates for the future U.S. sales of Orencia(R), we anticipate cash receipts in excess of $100 million over the term of the license.

Quarterly Conference Call

Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, June 12th at 11:00 a.m. EDT, to review fourth quarter and fiscal year 2008 financial results and expectations and provide a quarterly update of the Company. Dr. Herlihy will be joined on the call
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading personal ... Black as Privacy Officer and Corporate Counsel. Black ... privacy laws as well as health care regulations. As ... will be responsible for reviewing, updating and enhancing the ... U.S. and abroad. She joined the company January 5, ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The Movement ... demonstration to support life extension technologies and awareness. The ... Universal Coordinated Time, on March 21st 2015, in a ... , Eric Schulke, Founder of MILE, says, “Our ... with urgency. The Movement for Indefinite Life Extension is ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 423andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3
... Conn., March 29, 2011 USChina Channel LLC announced today: ... Commonwealth Biotechnologies Inc. ("CBI") filed Form 8-k of SEC, to ... The vote process is going very well. We ... stock made the vote. Followings are the interim vote results ...
... March 29, 2011 AMDeC, LLC ... Program to include products offered by Sigma® Life ... of Sigma-Aldrich® (Nasdaq: SIAL).  AMDeC is a consortium ... New York region that is focused on increasing ...
... (OTC Bulletin Board: SNGX ) (Soligenix or ... financial results for the year ended December 31, 2010. ... December 31, 2010 were $1,947,628 as compared to $2,816,037 ... or 31%.  During 2009, Soligenix received a $1 million ...
Cached Biology Technology:Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 2Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 3Sigma® Life Science Joins AMDeC's Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers 2Sigma® Life Science Joins AMDeC's Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers 3Sigma® Life Science Joins AMDeC's Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers 4Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 2Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 3Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 4Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments 5
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... at the University of Cincinnati (UC) have found a ... to therapies to prevent the development of the nation,s ... findings will be presented for the first time at ... Nov. 17. The study, led by WenFeng Cai, ...
... a drug already approved for treating multiple sclerosis show ... bioterrorist attack with botulinum neurotoxin which is 10,000 ... known to man. The potential drugs also could be ... well as Alzheimer,s disease, multiple sclerosis, and myasthenia gravis, ...
... presented at the 2010 FIP Pharmaceutical Sciences World Congress ... Annual Meeting and Exposition will highlight a targeted inhalable ... of needle avoidance and expected lower cost than the ... world. HPV is the number one ...
Cached Biology News:Researchers discover potential genetic target for heart disease 2New needle-free HPV vaccine increases effectiveness, availability in developing world 2
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
... Convenient platform for tube handling and reagent dispensing ... V-bottom tubes - 96 x 0.3ml ... - Thermo-Fast® 96 Non-Skirted Plate ... 48 x 0.5ml Thermo-Tubes Multiple workstations can be securely ...
6B9...
Biology Products: